Technetium (99mTc) pentetic acid

Technetium (^99mTc) pentetic acid
Clinical data
Trade names	Draximage DTPA
License data	US DailyMed: Technetium tc 99m pentetate;
Routes of; administration	Intravenous, inhalation
ATC code	V09CA01 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	65454-61-7;
PubChem CID	73415750;
ChemSpider	25016281;
UNII	VW78417PU1;
Chemical and physical data
Formula	C14H18N3NaO10Tc
Molar mass	509 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Na+].[99Tc+4];
	InChI InChI=1S/C14H23N3O10.Na.Tc/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;/q;+1;+4/p-5; Key:VTPAYRVYYYAMJN-UHFFFAOYSA-I;

Technetium (^99mTc) pentetic acid, sold under the brand name Draximage DTPA among others, is a radiopharmaceutical medication used in nuclear medicine to image the brain, kidneys, or lungs.^[1] It is given by intravenous injection or via aerosol spray.^[1] It consists of technetium-99m bound to the conjugate base of pentetic acid, with sodium as an additional cation.

Medical uses

Technetium (^99mTc) pentetic acid is indicated for use in the diagnosis of the brain, kidneys, or lungs.^[1]

References

1 2 3 4 "Draximage DTPA- kit for the preparation of technetium tc 99m pentetate injection, powder, lyophilized, for solution". DailyMed. 8 November 2022. Archived from the original on 5 February 2023. Retrieved 4 February 2023.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Draximage_DTPA_FDA_label-1] 1 2 3 4 "Draximage DTPA- kit for the preparation of technetium tc 99m pentetate injection, powder, lyophilized, for solution". DailyMed. 8 November 2022. Archived from the original on 5 February 2023. Retrieved 4 February 2023.

[1]